MCID: SBC017
MIFTS: 38

Sebaceous Gland Disease

Categories: Skin diseases, Endocrine diseases

Aliases & Classifications for Sebaceous Gland Disease

MalaCards integrated aliases for Sebaceous Gland Disease:

Name: Sebaceous Gland Disease 12 15
Sebaceous Gland Diseases 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9098
ICD10 33 L70.8
ICD9CM 35 706.1

Summaries for Sebaceous Gland Disease

Disease Ontology : 12 A skin disease that is located in the sebaceous gland.

MalaCards based summary : Sebaceous Gland Disease, also known as sebaceous gland diseases, is related to neurofibromatosis, type ii and mycobacterium chelonae, and has symptoms including exanthema and pruritus. An important gene associated with Sebaceous Gland Disease is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are IL-17 Family Signaling Pathways and Diseases associated with the TLR signaling cascade. The drugs Tazarotene and Isotretinoin have been mentioned in the context of this disorder. Affiliated tissues include the sebaceous gl, skin and testes.

Wikipedia : 76 Sebaceous glands are microscopic exocrine glands in the skin that secrete an oily or waxy matter, called... more...

Related Diseases for Sebaceous Gland Disease

Diseases related to Sebaceous Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 37)
# Related Disease Score Top Affiliating Genes
1 neurofibromatosis, type ii 31.2 DEFB4A IL1A SHBG TLR2
2 mycobacterium chelonae 10.7 CXCL8 TLR2
3 mycobacterium kansasii 10.6 CXCL8 TLR2
4 neurosyphilis 10.6 CXCL8 TLR2
5 haemophilus influenzae 10.6 CXCL8 TLR2
6 mycobacterium abscessus 10.6 CXCL8 TLR2
7 necrotizing fasciitis 10.6 CXCL8 IER3IP1
8 tuberculous meningitis 10.5 CXCL8 TLR2
9 acute cystitis 10.5 CXCL8 IER3IP1
10 rosacea 10.5 IER3IP1 TLR2
11 irritant dermatitis 10.5 IER3IP1 IL1A
12 anal canal squamous cell carcinoma 10.5 NCSTN PSENEN
13 vaginal disease 10.5 CXCL8 DEFB4A
14 vaginitis 10.5 CXCL8 DEFB4A
15 leukoregulin 10.4 CXCL8 IL1A
16 sinusitis 10.4 CXCL8 DEFB4A
17 scabies 10.4 CXCL8 IL1A
18 hidradenitis suppurativa 10.3 NCSTN PSENEN
19 middle ear disease 10.3 CXCL8 TLR2
20 radiculopathy 10.3 CXCL8 IL1A
21 hidradenitis 10.3 NCSTN PSENEN
22 aseptic meningitis 10.3 CXCL8 IL1A
23 dental pulp disease 10.3 CXCL8 NPS
24 pyoderma gangrenosum 10.3 CXCL8 PSTPIP1
25 septic arthritis 10.2 CXCL8 DEFB4A TLR2
26 sweat gland disease 10.2 NCSTN PSENEN PSTPIP1
27 pulpitis 10.2 CXCL8 IL1A
28 dermatitis, atopic 10.2 CXCL8 DEFB4A TLR2
29 periodontitis 10.1 CXCL8 IL1A TLR2
30 dysentery 10.1 IER3IP1 IL1A
31 pyoderma 10.1 CXCL8 PSTPIP1
32 acquired metabolic disease 10.0 IER3IP1 IGF1 SHBG
33 oral candidiasis 10.0 CXCL8 DEFB4A IL1A
34 gingivitis 10.0 CXCL8 DEFB4A IL1A
35 bacterial vaginosis 9.7 CXCL8 DEFB4A IL1A TLR2
36 periodontal disease 9.7 CXCL8 DEFB4A IL1A TLR2
37 bullous keratopathy 9.6 CXCL8 IL1A

Graphical network of the top 20 diseases related to Sebaceous Gland Disease:



Diseases related to Sebaceous Gland Disease

Symptoms & Phenotypes for Sebaceous Gland Disease

UMLS symptoms related to Sebaceous Gland Disease:


exanthema, pruritus

Drugs & Therapeutics for Sebaceous Gland Disease

Drugs for Sebaceous Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 209)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tazarotene Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 118292-40-3 5381
2
Isotretinoin Approved Phase 4,Phase 1 4759-48-2 5538 5282379
3
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 564-25-0 54671203
4
Benzoyl peroxide Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 94-36-0 7187
5
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 69-72-7 338
6
Adapalene Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106685-40-9 60164
7
Azelaic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 123-99-9 2266
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 22916-47-8 4189
9
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 18323-44-9 29029
10
Ciclopirox Approved, Investigational Phase 4,Phase 3 29342-05-0 2749
11
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
12
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
13
Norgestrel Approved Phase 4 6533-00-2 13109
14
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 10118-90-8 5281021
15
Moxifloxacin Approved, Investigational Phase 4,Phase 1 354812-41-2, 151096-09-2 152946
16
Desogestrel Approved Phase 4 54024-22-5 40973
17 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 979-32-8
18
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
19
Norgestimate Approved, Investigational Phase 4,Phase 1 35189-28-7 6540478
20
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
21
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 50-28-2 5757
22
Dapsone Approved, Investigational Phase 4,Phase 3,Phase 1 80-08-0 2955
23
Ketoconazole Approved, Investigational Phase 4,Phase 3,Not Applicable 65277-42-1 47576 3823
24
Cyproterone Acetate Approved, Investigational Phase 4,Phase 3 427-51-0
25
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 1 57-63-6 5991
26
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 1 28014-46-2
27
Coal tar Approved Phase 4,Not Applicable 8007-45-2
28
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 98-92-0 936
29
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 59-67-6 938
30
Tretinoin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 302-79-4 5538 444795
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
32
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 1 58-05-9 143 6006
33 tannic acid Approved, Nutraceutical Phase 4
34 Nadifloxacin Investigational Phase 4,Phase 3 124858-35-1
35 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Adapalene, Benzoyl Peroxide Drug Combination Phase 4,Phase 3,Phase 1,Not Applicable
37 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
38 Salicylates Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
39 Clindamycin palmitate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Clindamycin phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
42 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Nicotinic Acids Phase 4,Phase 3,Phase 2,Phase 1
44 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 1
45 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
46 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
48 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2
49 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 371)
# Name Status NCT ID Phase Drugs
1 Pilot Study of Tolerability and Effectivity of Two Combination Topical Acne Products Unknown status NCT02731105 Phase 4 Acnatac® Gel left face;Epiduo® Gel right face;Acnatac® Gel right face;Epiduo® Gel left face
2 Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris Unknown status NCT01448733 Phase 4 Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
3 A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne Unknown status NCT01422785 Phase 4 clindamycin phosphate 1.2%/tretinoin 0.025% gel alone;clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
4 Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples) Unknown status NCT01260571 Phase 4 Benzoyl peroxide and sulfur
5 Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
6 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris Completed NCT02959970 Phase 4 dapsone gel
7 A Treatment for Severe Inflammatory Acne Subjects Completed NCT02899000 Phase 4 Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel;Oral doxycycline hyclate
8 Tazarotene Plus Clindamycin vs. Adapalene Plus Clindamycin in the Treatment of Facial Acne Vulgaris Completed NCT02721173 Phase 4 Tazarotene 0.1% gel plus clindamycin 1% gel;Adapalene 0.1% gel plus clindamycin 1% gel
9 Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris Completed NCT02589405 Phase 4 Benzoyl Peroxide
10 DUAC® Early Onset Efficacy Study in Japanese Subjects Completed NCT02557399 Phase 4 Duac® fixed dose combination gel;ADA 0.1% gel;CLDM 1% gel
11 8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne Completed NCT02524665 Phase 4
12 A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris Completed NCT02249104 Phase 4 Adapalene/benzoyl peroxide gel, 0.1%/2.5%
13 Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris Completed NCT02058628 Phase 4 Clindamycin + BPO;Azelaic acid
14 A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris Completed NCT02032407 Phase 4 Dapsone Gel
15 Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris Completed NCT01951417 Phase 4 Adapalene/BPO Gel
16 Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel Completed NCT01885910 Phase 4 Doxycycline 100mg;Aczone 5% gel
17 U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne Completed NCT01706263 Phase 4 MAXCLARITY II (2.5% BPO) Foam Cleanser;MAXCLARITY II (2.5% BPO) Foam Treatment;MAXCLARITY II (0.5% Salicylic Acid) Toner Foam
18 U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™ Completed NCT01706250 Phase 4
19 Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel Completed NCT01522456 Phase 4 Epiduo Gel;Retin-A Micro Microsphere 0.1%
20 Effect of Samples on Acne Treatment With Epiduo® Gel Completed NCT01504204 Phase 4 Adapalene + benzoyl peroxide samples;Adapalene + benzoyl peroxide from standard tube
21 An Efficacy and Safety Study Comparing Oral Contraceptive Containing Norgestimate or Desogestrel for Acne Treatment Completed NCT01466673 Phase 4 Ethinyl estradiol/Norgestimate (EE/NGM);Ethinyl estradiol/Desogestrel (EE/DSG)
22 A Pilot Study of the Effects of Isotretinoin on Cognition, Learning and Memory Completed NCT01404130 Phase 4 Isotretinoin
23 Study for Long-term Treatment of Acne Vulgaris With Skinoren Versus Differin Completed NCT01387048 Phase 4 skinoren;differin;skinoren
24 A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products Completed NCT01313728 Phase 4 Dapsone plus Tretinoin Gel;Tretinoin Gel
25 A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne Completed NCT01231334 Phase 4 Dapsone plus Adapalene;Clindamycin/benzoyl peroxide plus Adapalene
26 Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris Completed NCT01209949 Phase 4 Adapalene 0.1% and Benzoyl Peroxide 2.5% gel
27 Anti Propionibacterium(P.) Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel Completed NCT01188538 Phase 4 Epiduo gel;BPO
28 Evaluation of Efficacy and Safety of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris Completed NCT01149330 Phase 4 Adapalene-BPO Gel
29 Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris Completed NCT01047189 Phase 4 clindamycin phosphate 1.2% and tretinoin 0.025%;clindamycin 1% gel;tretinoin 0.025% cream
30 A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris Completed NCT01016977 Phase 4 Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene;clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
31 Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications Completed NCT01015638 Phase 4 Clindamycin and BPO 5% gel;Clindamycin phosphate and benzoyl peroxide 2.5% gel.
32 Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications Completed NCT00964366 Phase 4 clindamycin and benzoyl peroxide;Dapsone gel
33 A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne Completed NCT00964223 Phase 4 Clindamycin and benzoyl peroxide gel (Duac® Topical Gel);benzoyl peroxide and adapalene gel (EPIDUO™ Gel)
34 Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face Completed NCT00952523 Phase 4 Tretinoin Facial Gel;Adapalene/Benzoyl Peroxide Facial Gel
35 Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications Completed NCT00926367 Phase 4 Clindamycin and benzoyl peroxide;benzoyl peroxide 2.5% and adapalene 0.1% gel
36 Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face Completed NCT00919191 Phase 4 Tretinoin gel;Adapalene and Benzoyl peroxide
37 A Study of Different Use Regimens Using Two Acne Treatments Completed NCT00907257 Phase 4 benzoyl peroxide wash;Tretinoin gel
38 A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne Completed NCT00887484 Phase 4 BENZOYL PEROXIDE/ CLINDAMYCIN;BENZOYL PEROXIDE/ ADAPALENE
39 Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne Completed NCT00841776 Phase 4 Duac;Ziana gel
40 Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris Completed NCT00835198 Phase 4 Dapsone; Tretinoin;Tretinoin
41 Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris Completed NCT00834210 Phase 4 Dapsone;Tazarotene
42 Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to Differin® Gel in the Treatment of Acne Completed NCT00807014 Phase 4 Duac Gel;Differin gel
43 Injectable POLY-L-Lactic Acid for Treatment of Hill and Valley Acne Scarring Completed NCT00795327 Phase 4
44 Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris Completed NCT00757523 Phase 4 Epiduo Gel;Duac Gel
45 Comparison of Efficacy and Safety of Norgestimate-ethinyl Estradiol and Cyproterone Acetate-ethinyl Estradiol in the Treatment of Acne Vulgaris Completed NCT00752635 Phase 4 Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol
46 Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face. Completed NCT00714714 Phase 4 Adapalene Gel;Tretinoin Gel
47 Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris Completed NCT00696449 Phase 4 Adapalene
48 Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris Completed NCT00671749 Phase 4 adapalene gel, 0.3%;clindamycin/benzoyl peroxide gel
49 Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1% Completed NCT00660985 Phase 4 Adapalene;Adapalene
50 Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne Completed NCT00658112 Phase 4 Benzoyl Peroxide

Search NIH Clinical Center for Sebaceous Gland Disease

Genetic Tests for Sebaceous Gland Disease

Anatomical Context for Sebaceous Gland Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Sebaceous Gland Disease:

19
The Sebaceous Gl

MalaCards organs/tissues related to Sebaceous Gland Disease:

41
Skin, Testes, Brain, Bone

Publications for Sebaceous Gland Disease

Variations for Sebaceous Gland Disease

Expression for Sebaceous Gland Disease

Search GEO for disease gene expression data for Sebaceous Gland Disease.

Pathways for Sebaceous Gland Disease

Pathways related to Sebaceous Gland Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.97 CXCL8 DEFB4A TLR2
2
Show member pathways
11.89 CXCL8 IL1A TLR2
3
Show member pathways
11.83 CXCL8 IL1A TLR2
4
Show member pathways
11.77 IL1A NCSTN PSENEN
5
Show member pathways
11.72 CXCL8 DEFB4A TLR2
6 11.36 CXCL8 IGF1 IL1A
7 11.09 CXCL8 IL1A TLR2
8 10.62 NCSTN PSENEN
9 10.03 CXCL8 NCSTN PSENEN

GO Terms for Sebaceous Gland Disease

Cellular components related to Sebaceous Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gamma-secretase complex GO:0070765 8.62 NCSTN PSENEN

Biological processes related to Sebaceous Gland Disease according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.81 CXCL8 DEFB4A IL1A TLR2
2 inflammatory response GO:0006954 9.73 CXCL8 IL1A PSTPIP1 TLR2
3 positive regulation of mitotic nuclear division GO:0045840 9.49 IGF1 IL1A
4 membrane protein ectodomain proteolysis GO:0006509 9.48 NCSTN PSENEN
5 membrane protein intracellular domain proteolysis GO:0031293 9.46 NCSTN PSENEN
6 cell activation GO:0001775 9.4 IGF1 TLR2
7 Notch receptor processing GO:0007220 9.37 NCSTN PSENEN
8 response to molecule of bacterial origin GO:0002237 9.32 CXCL8 TLR2
9 Notch receptor processing, ligand-dependent GO:0035333 9.26 NCSTN PSENEN
10 amyloid precursor protein metabolic process GO:0042982 9.16 NCSTN PSENEN
11 amyloid precursor protein catabolic process GO:0042987 8.96 NCSTN PSENEN
12 amyloid-beta formation GO:0034205 8.62 NCSTN PSENEN

Sources for Sebaceous Gland Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....